



Total synthesis of 20-hydroxy-hepoxilins, new metabolites of the hepoxilin family

Peter M. Demin,^{a,b} Tatjana A. Manukina,^a Cecil R. Pace-Asciak,^{b,c} and Kasimir K. Pivnitsky^{*a}

^a Institute of Experimental Endocrinology of the National Endocrinology Scientific Centre, Russian Academy of Medical Sciences, 115478 Moscow, Russian Federation. Fax: +7 095 310 7000

^b Research Institute, Hospital for Sick Children, 555 University Avenue, Toronto, M5G 1X8 Canada.

^c Department of Pharmacology, Faculty of Medicine, University of Toronto, Toronto, M5S 1A8 Canada.


A newly described enzymatically formed ω -hydroxy metabolite of hepoxilin A₃ (HxA₃) has been prepared *via* total synthesis involving polyacetylenic intermediates and Mitsunobu rearrangement of the intermediate putative ω -hydroxy metabolite of hepoxilin B₃.

We have recently observed that HxA₃ is metabolised by intact human neutrophils through a new pathway involving ω -oxidation.¹ The metabolite was shown to be ω -hydroxy-HxA₃, demonstrating that the intact human neutrophils lack metabolism of hepoxilins *via* the epoxide hydrolase pathway that was identified previously in other tissues for the metabolism of hepoxilins.^{2,3} We describe herein the total chemical synthesis of 20-hydroxy-HxA₃ which is identical to the metabolite formed by human neutrophils. This metabolite is biologically active on human neutrophils causing the release of intracellular calcium and is able to bind competitively to the putative hepoxilin receptor in these cells.¹

(2S,3S)-Epoxy-1,11-dihydroxyundec-5-yne **1** served as a key synthon. The diol **1** was obtained starting from 1,5-dibromopentane **2**. Its condensation with 1 equiv. of lithio-1-tetrahydropyranyloxyprop-2-yne in DMSO followed by OTHP→OH→Br exchange (see Scheme 1) produced the dibromide **3** in 26% overall yield. The condensation of

dibromide **3** with propargyl alcohol under the conditions described⁴ proceeded selectively at the 1-position of the molecule; in this reaction the aliphatic bromine exchanges with iodine, thus producing cleanly (yield 85%) the diacetylenic hydroxyiodide **4**. The future 20-hydroxyl functionality was created *in situ* by exchange of the iodide **4** with an acetate ion affording the acetate **5** in 81% overall yield. Reduction of the propargylic triple bond with LiAlH₄ accompanied by simultaneous acetate reduction was followed by Sharpless asymmetric epoxidation of the formed allylic *trans*-double bond and led to the key synthon **1** in 51% overall yield. The enantiomeric purity of synthon **1** was increased up to ee >95% by crystallisation, mp 24–26 °C (EtOAc) and confirmed by HPLC analysis of its mono-*tert*-butyldiphenylsilyl (BDPS) ether **7** on a chiral stationary phase.[†]

Several approaches were tested to differentiate the two hydroxyl groups of the diol **1** and to prepare the desired corresponding 1-aldehyde **8**. Oxidation under mild conditions



Scheme 2 Reagents and conditions: i, $\text{HC}\equiv\text{CCH}_2\text{Cl}$, Bu^nLi , Et_2O , -70°C , 15 min; ii, $\text{HC}\equiv\text{C}(\text{CH}_2)_3\text{COOMe}$, CuI , NaI , K_2CO_3 , 20°C , 12 h; iii, H_2 , Lindlar, quinoline, 20°C , 60 min; iv, Bu_4NF , THF , 20°C , 3 h; v, PhCOOH , DEAD , PPh_3 , THF , 20°C , 5 min; vi, MeONa , MeOH , 20°C , 3 h.

(10*R*)-epimer **12b** was transformed with partial allylic rearrangement into a 1:1 mixture of the pair of 20-hydroxy- HxA_3 methyl esters **14a,b** and 20-hydroxy- HxB_3 **12a**, whereas for the (10*S*)-epimer **12a** gave **12b** exclusively. The two 8-epimeric 20-hydroxy- HxA_3 methyl esters **14a,b** as well as the intermediate dibenzoates **13a,b** were indistinguishable both chromatographically and spectrometrically.*

The chromatographic and spectral data obtained for the synthetic sample of 20-hydroxy- HxA_3 methyl ester **14** were identical to those of the methylated biological sample of ω -hydroxy metabolite of HxA_3 prepared by incubation of HxA_3 methyl ester with human neutrophils.¹ The results of the biological testing of these synthetic heptoxilin metabolites will be reported in due course.

This work was supported by grant no. MT-4181 to C.R. Pace-Asciak from the Medical Research Council of Canada and by grant no. 96-03-34439 to K. K. Pivnitsky from the Russian Foundation for Basic Research.

References

- 1 D. Reynaud, O. Rounova, P. M. Demin, K. K. Pivnitsky and C. R. Pace-Asciak, to be published.
- 2 C. R. Pace-Asciak, D. Reynaud and P. M. Demin, *Lipids*, 1995, **30**, 107.
- 3 C. R. Pace-Asciak, *Biochim. Biophys. Acta*, 1994, **1215**, 1.

- 4 M. A. Lapitskaya, L. L. Vasiljeva and K. K. Pivnitsky, *Synthesis*, 1993, 65.
- 5 S. Hanessian and P. Lavalley, *Can. J. Chem.*, 1975, **53**, 2975.
- 6 P. M. Demin, K. K. Pivnitsky, L. L. Vasiljeva and C. R. Pace-Asciak, *J. Labelled Comp. Radiopharm.*, 1994, **34**, 221.
- 7 L. L. Vasiljeva, T. A. Manukina, P. M. Demin, M. A. Lapitskaya and K. K. Pivnitsky, *Tetrahedron*, 1993, **49**, 4099.

Received: Moscow, 6th February 1996

Cambridge, 26th February 1996; Com. 6/01009A